9th Oct 2006 07:00
Stem Cell Sciences plc09 October 2006 Embargoed until 07.00 9 October 2006 Stem Cell Sciences plc ("Stem Cell Sciences" or "the Group") Stem Cell Sciences' Board Strengthened for US Development Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused onthe commercialisation of stem cells and stem cell technologies in research andnovel cell-based therapies, is pleased to announce the appointment of David ADodd to the Stem Cell Sciences' Board as Non-executive Director with immediateeffect. Mr. Dodd, aged 57, brings a wealth of commercial and corporate Life Sciencesexperience to the Group. He was President, Chief Executive Officer and Directorof NASDAQ quoted Serologicals Corporation until it was acquired by the MilliporeCorporation on 14 July 2006. During Mr. Dodd's six year leadership, the value ofSerologicals Corporation increased from $85 million to $1.4 billion. From August 1995 until June 2000, he served as President and Chief ExecutiveOfficer of Solvay Pharmaceuticals Inc. and as a member of the Management Boardfor the Pharmaceutical Sector for Solvay S.A. Mr. Dodd was also Chairman of theBoard of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals.Prior to joining Solvay, he served in a number of management and executivepositions with major life science corporations, including Wyeth, Bristol-MyersSquibb, and Abbott Laboratories. Mr. Dodd currently serves on the board of a number of not-for-profitorganisations including; the Board of the Georgia Biomedical Partnership, asImmediate Past-Chair; on the Board of the Southern BioAlliance; and, is Chairmanof the Board of the American Foundation for Suicide Prevention. Additionally hesits on the Advisory Board of the Institute for Bioengineering and Bioscience,Georgia Tech/Emory University and the International Development Board, of theUniversity of Dundee, Scotland. He recently was awarded the 2005 GBP Biomedical Industry Growth Award for hisefforts in promoting Georgia's life sciences industry. In addition, Mr. Doddreceived the 2005 Oglethorpe Award from the Atlanta Chapter of the BritishAmerican Business Group, in recognition of his ongoing leadership in fosteringbusiness relationships between the U.S. and the United Kingdom. David holds a Bachelor of Science and Master of Science from Georgia StateUniversity and completed the Harvard Business School Advanced ManagementProgram. Dr Michael Dexter, Chairman of Stem Cell Sciences said: "The appointment ofDavid brings considerable strengths to our Board and will greatly assist us inmeeting our targets for expansion into US markets." Commenting on his appointment David Dodd said: "I am delighted to be joining theStem Cell Sciences' team. I look forward to bringing my own experience to theBoard and assisting Stem Cell Sciences in the development of the Group'sexciting plans for the business, particularly in the United States where we areseeing very exciting times for stem cell research." Stem Cell Sciences' Chief Executive, Peter Mountford said: "We are delightedthat David has accepted our invitation to join the Board. I am sure hisextensive knowledge of the life science industry and depth of experience ininternational business will add great value to our global business initiative." Current Commercial Appointments held --------------------------------------------------------------------------------Company Name Position Appointed --------------------------------------------------------------------------------None -------------------------------------------------------------------------------- Past Appointments Held --------------------------------------------------------------------------------Name Position Appointed Resigned --------------------------------------------------------------------------------Serologicals Corporation President, CEO June 2000 July 2006 and Director --------------------------------------------------------------------------------Solvay Pharmaceuticals Inc President and August 1995 June 2000 CEO --------------------------------------------------------------------------------Unimed Pharmaceuticals Inc Chairman July 1995 June 2000--------------------------------------------------------------------------------American Home Products/Wyeth Senior Vice March 1995 July 1995 Ayerst Laboratories President --------------------------------------------------------------------------------American Home Products/Wyeth Vice President February 1991 Promoted Ayerst Laboratories and General March 1995 Manager --------------------------------------------------------------------------------Bristol Myers Squibb/Mead General Manager August 1990 February 1991 Johnson Laboratories Division --------------------------------------------------------------------------------Bristol Myers Squibb/Mead Director of October 1986 Promoted Johnson Laboratories Division Marketing August 1990-------------------------------------------------------------------------------- - Ends - For further information, please contact: Stem Cell Sciences plc 0131 662 9829Michael Dexter, ChairmanPeter Mountford, Chief Executive OfficerHugh Ilyine, Chief Operating OfficerSue Furber, Director of Finance & Company Secretary Weber Shandwick | Square Mile 020 7067 0700James White Notes to Editors Stem Cell Sciences plc Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology companyproviding products in the burgeoning stem cell research and drug discoverymarkets, in addition to the targeted development of cell-based therapies forneurodegenerative disease and injury. The Company has established a leading intellectual property (IP) and technologyportfolio that provides a single platform of stem cells and stem celltechnologies for both research and clinical application. Revenue streams andtechnology development for the scaled production of stem cells in basic researchand drug discovery underpin the company's longer term plans to be a leadingprovider of cell-based therapeutics. SCS' principal focus is in neurological disease. Total revenues for the globalneurotech market, including pharmaceuticals, devices and diagnostics, grew 10%in 2005 to US$110 billion*. SCS operates as a global group with laboratories in Scotland, Japan andAustralia, each of which is affiliated with an academic centre of excellence.These include the Institute of Stem Cell Research (ISCR), Edinburgh, UK; RIKENCentre for Development Biology, Kobe, Japan and the Australian Stem Cell Centre,Melbourne, Australia. SCS has four business units focused on key sustainable business strategies. SC Proven(R) provides cell culture media (liquid formulations) and reagents thatenable the growth and differentiation of stem cells. The first commerciallyavailable product, a novel, serum free, stem cell growth medium, has beenexclusively licensed for manufacture and marketing to Chemicon International(part of the Millipore Group). SC Licensing licenses SCS proprietary technologies, such as Internal RibosomeEntry Site (IRES) and Stem Cell Selection, for application in laboratory-basedresearch and discovery. SCS has licensed technology to major pharmaceutical andbiotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc andLexicon Genetics Inc. SC Services provides specialised stem cell production for basic research anddrug discovery, including high-throughput applications. SC Therapies goal is to develop safe and effective cell-based therapies forcurrently incurable diseases. SCS is evaluating proprietary technologies inearly stage research for future cell therapy applications. *Neurotech Insights, Volume 2/3 April 30 2006. Serologicals Corporation Serologicals Corporation, headquartered in Atlanta, Georgia, was a globalprovider of biological products, enabling technologies and custom services tolife science companies and research organizations. The Company's diversecustomer base included major life science companies and leading researchinstitutions. Prior to its recent purchase, Serologicals had approximately 1000employees worldwide, and its shares were traded on the NASDAQ national stockmarket under the symbol SERO. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree